Published in Clinical Trials Week, December 26th, 2005
"Dalbavancin, a novel lipoglycopeptide with a pharmacokinetic profile that allows weekly dosing, is active against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA)," scientists in Pennsylvania explained. The efficacy of dalbavancin for SSSI treatment was previously "demonstrated in a phase 2 study."
"In a phase 3 noninferiority study," conducted by L.E. Jauregui and colleagues working at Vicuron Pharmaceuticals, "patients with complicated SSSIs,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.